The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.22 billion COVID-19 vaccine doses to 144 countries, GAVI data shows.
In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
The following tables list countries that have received vaccines under the scheme, sorted alphabetically:
AFRICA & MIDDLE EAST
COUNTRY LATEST DELIVERY DATE VACCINE TYPE POPULATION TOTAL
DELIVERY DELIVERED
Algeria 3.6 million December 24 J&J 44 million 6.0 million
Angola 801,000 December 25 Pfizer/BioNTech 33 million 14.8 million
Benin 336,000 November 4 J&J 12 million 1.1 million
Botswana 300,000 October 1 AstraZeneca/Oxford 2.5 million 560,460
Burkina Faso 504,000 December 22 J&J 21 million 1.1 million
Cameroon 336,000 November 5 J&J 27 million 1.0 million
Cape Verde 200,000 December 7 Pfizer/BioNTech 556,000 324,000
Central 168,300 November 19 J&J 4.8 million 806,700
African
Republic
Chad 117,000 October 5 Pfizer/BioNTech 16 million 217,620
Comoros 12,000 April 12 AstraZeneca/Oxford 870,000 12,000
Islands
Congo 168,000 November 15 J&J 5.5 million 470,400
Democratic 349,830 October 21 Pfizer/BioNTech 90 million 2.6 million
Republic of
Congo
Djibouti 151,200 July 17 J&J 988,000 175,200
Egypt 2.2 million February 20 Pfizer/BioNTech 102 million 29.0 million
Eswatini 100,620 October 6 Pfizer/BioNTech 1.1 million 429,420
Ethiopia 13.1 February 2 J&J 115 million 27.5 million
million
Gabon 101,790 November 1 Pfizer/BioNTech 2.2 million 370,410
Gambia 38,400 August 22 AstraZeneca/Oxford 2.4 million 376,800
Ghana 1.7 million December 24 Pfizer/BioNTech 31 million 16.3 million
Guinea 168,000 November 14 J&J 13 million 1.7 million
Guinea-Bissau 28,800 August 18 AstraZeneca/Oxford 2.0 million 360,000
Iran 700,000 January 14 AstraZeneca/Oxford 84 million 5.7 million
Iraq 500,000 August 14 Pfizer/BioNTech 40 million 836,000
Ivory Coast 816,660 January 3 Pfizer/BioNTech 26 million 8.6 million
Jordan 146,400 June 3 AstraZeneca/Oxford 10 million 436,800
Kenya 500,000 January 29 Pfizer/BioNTech 54 million 16.7 million
Lebanon 613,340 December 22 N/A 6.8 million 982,940
Lesotho 169,070 November 19 J&J 2.1 million 644,090
Liberia 168,000 November 27 J&J 5.1 million 830,400
Libya 1.2 million December 20 Pfizer/BioNTech 6.9 million 1.9 million
Madagascar 240,000 February 17 J&J 28 million 1.9 million
Malawi 360,000 October 23 AstraZeneca/Oxford 19 million 1.8 million
Mali 50,400 January 7 AstraZeneca/Oxford 20 million 1.7 million
Mauritania 201,600 February 7 AstraZeneca/Oxford 4.6 million 2.2 million
Mauritius 203,580 January 12 Pfizer/BioNTech 1.3 million 387,270
Morocco 1.5 million January 29 Pfizer/BioNTech 37 million 2.7 million
Mozambique 1.2 million February 11 AstraZeneca/Oxford 31 million 8.4 million
Namibia 168,000 February 18 J&J 2.5 million 492,800
Niger 398,000 February 4 Pfizer/BioNTech 24 million 1.6 million
Nigeria 2.0 million February 7 J&J 206 million 17.2 million
Palestinian 203,580 January 31 Pfizer/BioNTech 4.7 million 1.3 million
Territories
Rwanda 1.1 million January 15 N/A 13 million 3.9 million
Sao Tome and 24,000 March 3 AstraZeneca/Oxford 219,000 24,000
Principe
Senegal 302,400 February 10 J&J 17 million 3.2 million
Seychelles 39,780 December 17 Pfizer/BioNTech 98,460 74,880
Sierra Leone 168,000 November 23 J&J 8.0 million 785,310
Somalia 336,500 November 7 J&J 16 million 1.2 million
South Africa 5.6 million July 31 Pfizer/BioNTech 59 million 5.6 million
South Sudan 336,000 December 21 J&J 11 million 908,450
Sudan 604,800 February 16 J&J 44 million 3.9 million
Syria 4.0 million January 26 J&J 17 million 5.7 million
Tanzania 1.6 million January 19 Pfizer/BioNTech 60 million 4.7 million
Togo 633,600 November 25 J&J 8.3 million 3.0 million
Tunisia 310,050 January 28 Pfizer/BioNTech 12 million 4.4 million
Uganda 433,300 February 16 Moderna 46 million 11.7 million
Yemen 100,800 February 24 AstraZeneca/Oxford 30 million 2.2 million
Zambia 907,200 January 28 N/A 18 million 4.0 million
Zimbabwe 2.6 million January 19 N/A 15 million 3.5 million
EUROPE
COUNTRY LATEST DELIVERY VACCINE TYPE POPULATION TOTAL
DELIVERY DATE DELIVERED
Albania 40,800 June 2 AstraZeneca/Oxford 2.8 million 120,000
Armenia 187,200 September 5 AstraZeneca/Oxford 3.0 million 261,200
Azerbaijan 84,000 April 4 AstraZeneca/Oxford 10 million 84,000
Bosnia 32,760 May 10 Pfizer/BioNTech 3.3 million 82,560
Georgia 43,200 March 13 AstraZeneca/Oxford 3.7 million 43,200
Kosovo 515,970 February 10 Pfizer/BioNTech 1.8 million 1.2 million
Moldova 100,620 January 27 Pfizer/BioNTech 2.6 million 744,620
Montenegro 24,000 March 28 AstraZeneca/Oxford 622,000 24,000
North 250,380 February 7 Pfizer/BioNTech 2.1 million 312,780
Macedonia
Serbia 115,200 August 25 AstraZeneca/Oxford 6.9 million 292,800
Ukraine 1.0 million January 19 Pfizer/BioNTech 44 million 8.8 million
ASIA & PACIFIC
COUNTRY LATEST DELIVERY DELIVERY VACCINE TYPE POPULATION TOTAL
DATE DELIVERED
Afghanistan 2.0 million February 2 J&J 39 million 9.0 million
Bangladesh 342,400 February 2 Pfizer/BioNTech 165 million 34.8 million
Brunei 24,000 April 2 AstraZeneca/Oxford 437,000 24,000
Cambodia 300,000 December 19 AstraZeneca/Oxford 17 million 2.9 million
East Timor 100,620 February 12 Pfizer/BioNTech 1.3 million 494,040
Fiji 50,400 November 18 Moderna 896,000 302,480
Indonesia 2.6 million January 28 AstraZeneca/Oxford 274 million 48.8 million
Kiribati 56,000 August 21 AstraZeneca/Oxford 119,000 104,000
Kyrgyzstan 149,760 February 1 Pfizer/BioNTech 6.6 million 800,300
Laos 1.7 million January 26 Pfizer/BioNTech 7.3 million 7.6 million
Malaysia 559,200 September AstraZeneca/Oxford 32 million 1.4 million
17
Maldives 210,600 January 28 Pfizer/BioNTech 541,000 664,540
Mongolia 899,730 October 6 Pfizer/BioNTech 3.3 million 1.3 million
Nauru 7,200 April 2 AstraZeneca/Oxford 10,830 7,200
Nepal 800,000 February 7 AstraZeneca/Oxford 29 million 14.2 million
Pakistan 1.5 million December 28 Moderna 221 million 39.1 million
Papua New 302,400 August 6 J&J 8.9 million 580,400
Guinea
Philippines 3.4 million February 15 Pfizer/BioNTech 110 million 51.8 million
Samoa 112,000 August 23 AstraZeneca/Oxford 198,410 136,000
Solomon 100,620 November 16 Pfizer/BioNTech 687,000 209,420
Islands
Sri Lanka 820,000 December 20 Pfizer/BioNTech 22 million 5.0 million
Tajikistan 501,200 February 21 AstraZeneca/Oxford 9.5 million 5.4 million
Tonga 7,000 February 15 N/A 106,000 67,800
Tuvalu 4,800 April 8 AstraZeneca/Oxford 11,800 4,800
Uzbekistan 2.8 million February 17 Moderna 34 million 12.7 million
Vanuatu 24,000 May 19 AstraZeneca/Oxford 307,000 24,000
Vietnam 6.3 million January 25 Pfizer/BioNTech 97 million 38.7 million
AMERICAS
COUNTRY LATEST DELIVERY VACCINE TYPE POPULATION TOTAL
DELIVERY DATE DELIVERED
Antigua and 19,200 November 22 N/A 98,000 60,000
Barbuda
Argentina 960,400 October 12 AstraZeneca/Oxford 45 million 3.9 million
Bahamas 57,330 October 18 Pfizer/BioNTech 393,000 124,530
Barbados 14,040 December 16 Pfizer/BioNTech 287,000 114,840
Belize 58,500 October 26 Pfizer/BioNTech 398,000 159,300
Bermuda 9,600 April 6 AstraZeneca/Oxford 64,000 9,600
Bolivia 1.3 million February 16 Pfizer/BioNTech 12 million 8.0 million
Brazil 2.0 million September 20 Sinovac 213 million 11.9 million
Chile 331,000 May 20 AstraZeneca/Oxford 19 million 489,400
Colombia 5.5 million January 3 Pfizer/BioNTech 51 million 16.5 million
Costa Rica 1.0 million February 11 Pfizer/BioNTech 5.1 million 1.4 million
Dominica 30,240 February 4 Moderna 72,000 133,920
Dominican 184,800 August 27 AstraZeneca/Oxford 11 million 463,200
Republic
Ecuador 1.5 million February 15 Pfizer/BioNTech 18 million 3.8 million
El Salvador 188,370 August 27 Pfizer/BioNTech 6.5 million 3.6 million
Grenada 69,030 December 16 Pfizer/BioNTech 113,000 114,630
Guatemala 680,940 January 27 Pfizer/BioNTech 17 million 5.0 million
Guyana 28,800 January 14 J&J 787,000 291,540
Haiti 151,200 February 14 Moderna 11 million 1.1 million
Honduras 250,040 October 28 Moderna 9.9 million 4.8 million
Jamaica 100,000 February 21 AstraZeneca/Oxford 3.0 million 1.7 million
Mexico 2.2 million May 27 AstraZeneca/Oxford 129 million 3.3 million
Nicaragua 993,600 January 24 J&J 6.6 million 4.7 million
Panama 74,400 September 15 AstraZeneca/Oxford 4.3 million 148,800
Paraguay 466,830 January 24 Pfizer/BioNTech 7.1 million 1.7 million
Peru 1.2 million November 10 Sinopharm 33 million 3.6 million
Saint Kitts and 21,600 April 7 AstraZeneca/Oxford 53,000 21,600
Nevis
Saint Lucia 7,200 December 28 J&J 184,000 197,430
Saint Vincent 70,200 December 14 Pfizer/BioNTech 111,000 115,800
and the
Grenadines
Suriname 64,800 December 14 AstraZeneca/Oxford 587,000 144,000
Trinidad and 84,000 November 27 Sinopharm 1.4 million 185,200
Tobago
Uruguay 50,400 September 1 AstraZeneca/Oxford 3.5 million 148,800
Venezuela 3.1 million January 17 Sinopharm 28 million 12.1 million
Sources: WHO, UNICEF, GAVI, releases from local authorities
(Compiled by Marta Frackowiak, Antonis Pothitos, Boleslaw Lasocki, Antonis Triantafyllou, Aleksandra Jasiurska and Elizaveta Gladun; Edited by David Evans and Bernadette Baum)
The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.
It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.
Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”
Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.
Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.
A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.
On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.
Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”
But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”
“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.
Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.
Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.
Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.
“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.
“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”
This report by The Canadian Press was first published Sept. 13, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.
The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.
Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.
“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”
The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.
A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.
Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.
“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.
Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.
The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.
“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.
This report by The Canadian Press was first published Sept. 11, 2024.
ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.
Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.
Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.
Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.
The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.
“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.
Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.
Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.
Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.
A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.
This report by The Canadian Press was first published Sept. 10, 2024.